Medizinische Universität Graz - Research portal
Zebisch Armin |
** = Publications listed in SCI/SSCI/Pubmed
2025
Full paper/article (Journal)
** Foßelteder, J; Brauchart, T; Schlacher, A; Sconocchia, T; Özkaya, E; Auinger, L; Schlenke, P; Sill, H; Zebisch, A; Reinisch, A
Engineered cytokine-expressing MSCs support ex vivo culture of human HSPCs and AML cells.
Exp Hematol. 2025; 104790
Doi: 10.1016/j.exphem.2025.104790
PubMed
FullText
FullText_MUG
2024
Full paper/article (Journal)
** Buerger, M; Amor, M; Akhmetshina, A; Bianco, V; Perfler, B; Zebisch, A; Weichhart, T; Kratky, D
Limited Alleviation of Lysosomal Acid Lipase Deficiency by Deletion of Matrix Metalloproteinase 12.
Int J Mol Sci. 2024; 25(20): 11001
Doi: 10.3390/ijms252011001
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Wurm, S; Waltersdorfer, M; Loindl, S; Moritz, JM; Herzog, SA; Bachmaier, G; Berghold, A; Kashofer, K; Beham-Schmid, C; Hoefler, G; Greinix, HT; Wölfler, A; Reinisch, A; Sill, H; Zebisch, A
Acute myeloid leukemia in the next-generation sequencing era : Real-world data from an Austrian tertiary cancer care center.
Wien Klin Wochenschr. 2024;
Doi: 10.1007/s00508-024-02463-w
Web of Science
PubMed
FullText
FullText_MUG
Review
** Moritz, J; Schwab, A; Reinisch, A; Zebisch, A; Sill, H; Wölfler, A
Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions.
Biomedicines. 2024; 12(3): 599
Doi: 10.3390/biomedicines12030599
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Clemo, N; Roman-Trufero, M; Auner, H; Butt, R; Zebisch, A; Chaida, P; Herzog, S; Fuchter, M
Efficacy of GCN2 inhibition by a novel small molecule AP030 in acute leukemia.
J CLIN ONCOL. 2024; 42(16):
[Poster]
Web of Science
2023
Full paper/article (Journal)
** Foßelteder, J; Pabst, G; Sconocchia, T; Schlacher, A; Auinger, L; Kashofer, K; Beham-Schmid, C; Trajanoski, S; Waskow, C; Schöll, W; Sill, H; Zebisch, A; Wölfler, A; Thomas, D; Reinisch, A
Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities.
Leukemia. 2023; 37(4): 843-853.
Doi: 10.1038/s41375-023-01848-6
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Pleyer, L; Vaisband, M; Drost, M; Pfeilstöcker, M; Stauder, R; Heibl, S; Sill, H; Girschikofsky, M; Stampfl-Mattersberger, M; Pichler, A; Hartmann, B; Petzer, A; Schreder, M; Schmitt, CA; Vallet, S; Melchardt, T; Zebisch, A; Pichler, P; Zaborsky, N; Machherndl-Spandl, S; Wolf, D; Keil, F; Hasenauer, J; Larcher-Senn, J; Greil, R
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.
Am J Hematol. 2023;
Doi: 10.1002/ajh.27046
Web of Science
PubMed
FullText
FullText_MUG
** Sconocchia, T; Foßelteder, J; Auinger, L; Özkaya, E; Benezeder, T; Lang, M; Beham-Schmid, C; Hoefler, G; Zebisch, A; Wölfler, A; Sill, H; Wolf, P; Strobl, H; Reinisch, A
BRAFV600E promotes DC3/monocyte differentiation in human gene-engineered HSPCs and causes multisystem histiocytosis.
Leukemia. 2023; 37(11): 2292-2296.
Doi: 10.1038/s41375-023-02019-3
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Review
** Gurnari, C; Robin, M; Godley, LA; Drozd-Sokolowska, J; Wlodarski, MW; Raj, K; Onida, F; Worel, N; Ciceri, F; Carbacioglu, S; Kenyon, M; Aljurf, M; Bonfim, C; Makishima, H; Niemeyer, C; Fenaux, P; Zebisch, A; Hamad, N; Chalandon, Y; Hellstroem-Lindberg, E; Voso, MT; Mecucci, C; Duarte, FB; Sebert, M; Fontbrune, FSD; Soulier, J; Shimamura, A; Lindsley, RC; Maciejewski, JP; Calado, RT; Yakoub-Agha, I; Mclornan, DP
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT
LANCET HAEMATOL. 2023; 10(12): E994-E1005.
Doi: 10.1016/S2352-3026(23)00265-X
Web of Science
PubMed
FullText
FullText_MUG
Editorial
** Seidel, MG; Brcic, L; Hoefler, G; Hutter, C; Minkov, M; Steffen, LS; Zebisch, A; Benesch, M
Concurrence of a kinase-dead BRAF and an oncogenic KRAS gain-of-function mutation in juvenile xanthogranuloma.
Pediatr Blood Cancer. 2023; 70(4):e30060
Doi: 10.1002/pbc.30060
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Lyssy, F; Lind, K; Zöscher, F; Zebisch, A; Wölfler, A; Pabst, G; Fosselteder, J; Reinisch, A; Sill, H; Dutta, S
Modelling drug resistance conferred by mono- and bi-allelic TP53 aberrations using isogenic AML cell lines
ONCOL RES TREAT. 2023; 46: 188-189.
[Poster]
Web of Science
FullText
2022
Full paper/article (Journal)
** Dutta, S; Moritz, J; Pregartner, G; Thallinger, GG; Brandstätter, I; Lind, K; Rezania, S; Lyssy, F; Reinisch, A; Zebisch, A; Berghold, A; Wölfler, A; Sill, H
Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.
Ann Hematol. 2022; 101(4):837-846
Doi: 10.1007/s00277-022-04766-2
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Geissler, K; Jäger, E; Barna, A; Gurbisz, M; Marschon, R; Graf, T; Nösslinger, T; Pfeilstöcker, M; Machherndl-Spandl, S; Stauder, R; Zebisch, A; Sill, H; Öhler, L; Kusec, R; Hoermann, G; Valent, P
Multistep pathogenesis of chronic myelomonocytic leukemia in patients.
Eur J Haematol. 2022; 109(1):50-57
Doi: 10.1111/ejh.13768
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Leisch, M; Pfeilstöcker, M; Stauder, R; Heibl, S; Sill, H; Girschikofsky, M; Stampfl-Mattersberger, M; Tinchon, C; Hartmann, B; Petzer, A; Schreder, M; Kiesl, D; Vallet, S; Egle, A; Melchardt, T; Piringer, G; Zebisch, A; Machherndl-Spandl, S; Wolf, D; Keil, F; Drost, M; Greil, R; Pleyer, L
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group.
Cancers (Basel). 2022; 14(10):
Doi: 10.3390/cancers14102459
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Editorial
** Zebisch, A; Sill, H
How do non-coding RNAs impact treatment regimens currently being used in AML?
Expert Rev Anticancer Ther. 2022; 22(4):331-333
Doi: 10.1080/14737140.2022.2049764
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Lembeck, A; Zebisch, A; Quehenberger, F; Wolfler, A
Pravalenz von Pilz- und Fisch-formigen Erythrozyten in verschiedenen hamatologischen Erkrankungen
ONCOL RES TREAT. 2022; 45(SUPPL 2):290-291.
[Poster]
Web of Science
** Pleyer, L; Vaisband, M; Pfeilstocker, M; Stauder, R; Heibl, S; Sill, H; Girschikofsky, M; Stampfl-Mattersberger, M; Tinchon, C; Hartmann, BL; Petzer, A; Schreder, M; Schmitt, CA; Vallet, S; Melchardt, T; Scagnetti, L; Zebisch, A; Machherndl-Spandl, S; Wolf, D; Keil, F; Hasenauer, J; Greil, R
Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT
BLOOD. 2022; 140: 1346-1349.
Doi: 10.1182/blood-2022-168521
[Oral Communication]
Web of Science
FullText
FullText_MUG
2021
Full paper/article (Journal)
** Berg, JL; Perfler, B; Hatzl, S; Mayer, MC; Wurm, S; Uhl, B; Reinisch, A; Klymiuk, I; Tierling, S; Pregartner, G; Bachmaier, G; Berghold, A; Geissler, K; Pichler, M; Hoefler, G; Strobl, H; Wölfler, A; Sill, H; Zebisch, A
Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.
Clin Epigenetics. 2021; 13(1): 1-1.
Doi: 10.1186/s13148-020-00979-2
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Berg, JL; Perfler, B; Hatzl, S; Uhl, B; Reinisch, A; Pregartner, G; Berghold, A; Penz, T; Schuster, M; Geissler, K; Prokesch, A; Müller-Tidow, C; Hoefler, G; Kashofer, K; Wölfler, A; Sill, H; Caraffini, V; Zebisch, A
EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity.
Leukemia. 2021; 35(5):1521-1526
Doi: 10.1038/s41375-021-01161-0
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Machherndl-Spandl, S; Jäger, E; Barna, A; Gurbisz, M; Marschon, R; Graf, T; Graf, E; Geissler, C; Hoermann, G; Nösslinger, T; Pfeilstöcker, M; Bettelheim, P; Zach, O; Weltermann, A; Heibl, S; Thaler, J; Zebisch, A; Sill, H; Stauder, R; Webersinke, G; Kusec, R; Ulsperger, E; Schneeweiss, B; Öhler, L; Germing, U; Valent, P; Tüchler, H; Geissler, K
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia.
Eur J Haematol. 2021; 107(2):265-274
Doi: 10.1111/ejh.13647
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Middeke, JM; Teipel, R; Röllig, C; Stasik, S; Zebisch, A; Sill, H; Kramer, M; Scholl, S; Hochhaus, A; Jost, E; Brümmendorf, TH; Naumann, R; Steffen, B; Serve, H; Altmann, H; Kunzmann, V; Einsele, H; Parmentier, S; Schaich, M; Burchert, A; Neubauer, A; Schliemann, C; Berdel, WE; Sockel, K; Stölzel, F; Platzbecker, U; Ehninger, G; Bornhäuser, M; Schetelig, J; Thiede, C, , Study, Alliance, Leukemia, (SAL)
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis.
Leuk Lymphoma. 2021; 62(6):1432-1440
Doi: 10.1080/10428194.2020.1864354
Web of Science
PubMed
FullText
FullText_MUG
** Zyulina, V; Yan, KK; Ju, B; Schwarzenberger, E; Passegger, C; Tam-Amersdorfer, C; Pan, Q; Sconocchia, T; Pollack, C; Shaner, B; Zebisch, A; Easton, J; Yu, J; Silva, JM; Strobl, H
The miR-424(322)/503 gene cluster regulates pro- versus anti-inflammatory skin DC subset differentiation by modulating TGF-β signaling.
Cell Rep. 2021; 35(4): 109049-109049.
Doi: 10.1016/j.celrep.2021.109049
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Short report/Letter
** Mayer, MC; Berg, JL; Perfler, B; Hatzl, S; Herzog, SA; Bachmaier, G; Berghold, A; Reinisch, A; Wölfler, A; Sill, H; Zebisch, A
miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms.
ANN HEMATOL. 2021; 100(11): 2845-2847.
Doi: 10.1007/s00277-021-04598-6
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Foßelteder, J; Schlacher, A; Pabst, G; Amtmann, B; Schöll, W; Kashofer, K; Beham-Schmid, C; Schlenke, P; Greinix, HT; Sill, H; Woelfler, A; Zebisch, A; Reinisch, A
Introduction and Genetic Correction of Calreticulin Mutations in Human Hematopoietic Stem and Progenitor Cells Sheds Light on MPN Pathogenesis
Blood. 2021; 138(S1):-Annual Meeting of the American Society of Hematology (ASH); DEC 11-14, 2021; Atlanta, USA.
Doi: 10.1182/blood-2021-147919
[Poster]
Web of Science
FullText
FullText_MUG
** Pabst, G; Foßelteder, J; Schlacher, A; Auinger, L; Martinez-Krams3, D; Ediriwickrema, A; Kashofer, K; Beham-Schmid, C; Greinix, HT; Woelfler, A; Schlenke, P; Sill, H; Zebisch, A; Majeti, R; Reinisch, A
Modeling the Development of SRSF2 Mutated Myeloid Malignancies By CRISPR/Cas9 Mediated Genome Engineering of Primary Human Hematopoietic Stem and Progenitor Cells
Blood. 2021; 138(S1):-Annual Meeting of the American Society of Hematology (ASH); DEC 11-14, 2021; Atlanta, USA.
Doi: 10.1182/blood-2021-149591
[Poster]
Web of Science
FullText
FullText_MUG
** Pleyer, L; Pfeilstocker, M; Stauder, R; Heibl, S; Sill, H; Girschikofsky, M; Stampfl-Mattesberger, M; Tinchon, C; Hartmann, B; Petzer, A; Petricevic, B; Schmitt, CA; Vallet, S; Geissler, K; Sperr, WR; Leisch, M; Egle, A; Melchardt, T; Piringer, G; Zebisch, A; Machherndl-Spandl, S; Wolf, D; Keil, F; Angermann, H; Drost, M; Larcher-Senn, J; Greil, R
Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission – a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry
Englisch. 2021; 138(S1):-Annual Meeting of the American Society of Hematology (ASH); DEC 11-14, 2021; Atlanta, USA.
Doi: 10.1182/blood-2021-145401
[Poster]
Web of Science
FullText
FullText_MUG
2020
Full paper/article (Journal)
** Anirudh, S; Rosenberger, A; Schwarzenberger, E; Schaefer, C; Strobl, H; Zebisch, A; Sill, H; Wölfler, A
TNFα Rescues Dendritic Cell Development in Hematopoietic Stem and Progenitor Cells Lacking C/EBPα.
Cells. 2020; 9(5):
Doi: 10.3390/cells9051223
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Caraffini, V; Geiger, O; Rosenberger, A; Hatzl, S; Perfler, B; Berg, JL; Lim, C; Strobl, H; Kashofer, K; Schauer, S; Beham-Schmid, C; Hoefler, G; Geissler, K; Quehenberger, F; Kolch, W; Athineos, D; Blyth, K; Wölfler, A; Sill, H; Zebisch, A
Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis.
Haematologica. 2020; 105(2):375-386
Doi: 10.3324/haematol.2018.209650
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Daga, S; Rosenberger, A; Kashofer, K; Heitzer, E; Quehenberger, F; Halbwedl, I; Graf, R; Krisper, N; Prietl, B; Höfler, G; Reinisch, A; Zebisch, A; Sill, H; Wölfler, A
Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling.
Am J Hematol. 2020; 95(10):1148-57
Doi: 10.1002/ajh.25918
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Dutta, S; Pregartner, G; Rücker, FG; Heitzer, E; Zebisch, A; Bullinger, L; Berghold, A; Döhner, K; Sill, H
Functional Classification of TP53 Mutations in Acute Myeloid Leukemia.
Cancers (Basel). 2020; 12(3):
Doi: 10.3390/cancers12030637
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Fan, K; Zebisch, A; Horny, K; Schrama, D; Becker, JC
Highly Expressed miR-375 is not an Intracellular Oncogene in Merkel Cell Polyomavirus-Associated Merkel Cell Carcinoma.
Cancers (Basel). 2020; 12(3):
Doi: 10.3390/cancers12030529
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Füreder, W; Sperr, WR; Heibl, S; Zebisch, A; Pfeilstöcker, M; Stefanzl, G; Jäger, E; Greiner, G; Schwarzinger, I; Kundi, M; Keil, F; Hoermann, G; Bettelheim, P; Valent, P
Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network.
Ann Hematol. 2020; 99(10):2303-2313
Doi: 10.1007/s00277-020-04214-z
Web of Science
PubMed
FullText
FullText_MUG
** Geissler, K; Jäger, E; Barna, A; Gurbisz, M; Graf, T; Graf, E; Nösslinger, T; Pfeilstöcker, M; Machherndl-Spandl, S; Stauder, R; Zebisch, A; Sill, H; Öhler, L; Kusec, R; Hörmann, G; Valent, P
Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia.
Int J Mol Sci. 2020; 21(17):
Doi: 10.3390/ijms21176057
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Geissler, K; Jäger, E; Barna, A; Gurbisz, M; Graf, T; Graf, E; Nösslinger, T; Pfeilstöcker, M; Tüchler, H; Sliwa, T; Keil, F; Geissler, C; Heibl, S; Thaler, J; Machherndl-Spandl, S; Zach, O; Weltermann, A; Bettelheim, P; Stauder, R; Zebisch, A; Sill, H; Schwarzinger, I; Schneeweiss, B; Öhler, L; Ulsperger, E; Kusec, R; Germing, U; Sperr, WR; Knöbl, P; Jäger, U; Hörmann, G; Valent, P
Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 Patients.
Int J Mol Sci. 2020; 21(8):
Doi: 10.3390/ijms21083025
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Hatzl, S; Perfler, B; Wurm, S; Uhl, B; Quehenberger, F; Ebner, S; Troppmair, J; Reinisch, A; Wölfler, A; Sill, H; Zebisch, A
Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia.
Cancers (Basel). 2020; 12(2):
Doi: 10.3390/cancers12020496
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Lim, CX; Lee, B; Geiger, O; Passegger, C; Beitzinger, M; Romberger, J; Stracke, A; Högenauer, C; Stift, A; Stoiber, H; Poidinger, M; Zebisch, A; Meister, G; Williams, A; Flavell, RA; Henao-Mejia, J; Strobl, H
miR-181a Modulation of ERK-MAPK Signaling Sustains DC-SIGN Expression and Limits Activation of Monocyte-Derived Dendritic Cells.
Cell Rep. 2020; 30(11): 3793-3805.
Doi: 10.1016/j.celrep.2020.02.077
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Sill, H; Zebisch, A; Haase, D
Acute Myeloid Leukemia and Myelodysplastic Syndromes with TP53 Aberrations - A Distinct Stem Cell Disorder.
Clin Cancer Res. 2020; 26(20):5304-5309
Doi: 10.1158/1078-0432.CCR-20-2272
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Short report/Letter
** Hatzl, S; Posch, F; Schulz, E; Gornicec, M; Deutsch, A; Beham-Schmid, C; Pichler, M; Greinix, H; Sill, H; Zebisch, A; Neumeister, P; Prochazka, KT
The Role of Immunohistochemical Overexpression of p53 as Adverse Prognostic Factor in Primary Testicular Diffuse Large B Cell Lymphoma.
Pathol Oncol Res. 2020; 26(4):2831-2833
Doi: 10.1007/s12253-020-00864-6
Web of Science
PubMed
FullText
FullText_MUG
** Pabst, G; Lind, K; Graf, R; Zebisch, A; Stölzel, F; Döhner, K; Heitzer, E; Reinisch, A; Sill, H
TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model.
Ann Hematol. 2020; 99(3):653-655
Doi: 10.1007/s00277-020-03920-y
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Zebisch, A; Winter, G; Kashofer, K; Hatzl, S; Uhl, B; Wurm, S; Wölfler, A; Greinix, HT; Hoefler, G; Sill, H
The role of germline mutation profiling in the selection of related donors for haematopoietic stem cell transplantation.
Bone Marrow Transplant. 2020; 55(7):1502-1505
Doi: 10.1038/s41409-019-0691-1
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Correction
** Ulz, P; Perakis, S; Zhou, Q; Moser, T; Belic, J; Lazzeri, I; Wölfler, A; Zebisch, A; Gerger, A; Pristauz, G; Petru, E; White, B; Roberts, CES; John, JS; Schimek, MG; Geigl, JB; Bauernhofer, T; Sill, H; Bock, C; Heitzer, E; Speicher, MR
Publisher Correction: Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection.
Nat Commun. 2020; 11(1): 1965-1965.
Doi: 10.1038/s41467-020-15799-4
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2019
Full paper/article (Journal)
** Aberer, F; Mader, JK; Holzgruber, J; Trummer, C; Schwetz, V; Pandis, M; Pferschy, PN; Greinix, H; Tripolt, NJ; Pieber, TR; Zebisch, A; Sill, H; Wölfler, A; Sourij, H
Feasibility and safety of using an automated decision support system for insulin therapy in the treatment of steroid-induced hyperglycemia in patients with acute graft-versus-host disease: A randomized trial.
J Diabetes Investig. 2019; 10(2):339-342
Doi: 10.1111/jdi.12919
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Daga, S; Rosenberger, A; Quehenberger, F; Krisper, N; Prietl, B; Reinisch, A; Zebisch, A; Sill, H; Wölfler, A
High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
Cancer Med. 2019; 8(4):1771-1778
Doi: 10.1002/cam4.2053
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Geissler, K; Jäger, E; Barna, A; Gurbisz, M; Marschon, R; Graf, T; Graf, E; Borjan, B; Jilch, R; Geissler, C; Hoermann, G; Esterbauer, H; Schwarzinger, I; Nösslinger, T; Pfeilstöcker, M; Tüchler, H; Reisner, R; Sliwa, T; Keil, F; Bettelheim, P; Machherndl-Spandl, S; Doleschal, B; Zach, O; Weltermann, A; Heibl, S; Thaler, J; Zebisch, A; Sill, H; Stauder, R; Webersinke, G; Petzer, A; Kusec, R; Ulsperger, E; Schneeweiss, B; Berger, J; Öhler, L; Germing, U; Sperr, WR; Knöbl, P; Jäger, U; Valent, P
The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical research.
Wien Klin Wochenschr. 2019; 131(17-18):410-418
Doi: 10.1007/s00508-019-1526-1
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Prochazka, KT; Pregartner, G; Rücker, FG; Heitzer, E; Pabst, G; Wölfler, A; Zebisch, A; Berghold, A; Döhner, K; Sill, H
Clinical implications of subclonal TP53 mutations in acute myeloid leukemia.
Haematologica. 2019; 104(3):516-523
Doi: 10.3324/haematol.2018.205013
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Ulz, P; Perakis, S; Zhou, Q; Moser, T; Belic, J; Lazzeri, I; Wölfler, A; Zebisch, A; Gerger, A; Pristauz, G; Petru, E; White, B; Roberts, CES; John, JS; Schimek, MG; Geigl, JB; Bauernhofer, T; Sill, H; Bock, C; Heitzer, E; Speicher, MR
Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection.
Nat Commun. 2019; 10(1): 4666-4666.
Doi: 10.1038/s41467-019-12714-4
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Short report/Letter
** Müller, M; Graf, R; Kashofer, K; Macher, S; Wölfler, A; Zebisch, A; Hrzenjak, A; Heitzer, E; Sill, H
Detection of AML-specific TP53 mutations in bone marrow-derived mesenchymal stromal cells cultured under hypoxia conditions.
Ann Hematol. 2019; 98(8):2019-2020
Doi: 10.1007/s00277-019-03680-4
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Review
** Zebisch, A; Caraffini, V; Sill, H
RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis.
Int J Mol Sci. 2019; 20(22):
Doi: 10.3390/ijms20225756
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2018
Full paper/article (Journal)
** Caraffini, V; Perfler, B; Berg, JL; Uhl, B; Schauer, S; Kashofer, K; Ghaffari-Tabrizi-Wizsy, N; Strobl, H; Wölfler, A; Hoefler, G; Sill, H; Zebisch, A
Loss of RKIP is a frequent event in myeloid sarcoma and promotes leukemic tissue infiltration.
Blood. 2018; 131(7): 826-830.
Doi: 10.1182/blood-2017-09-804906
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Gaksch, L; Kashofer, K; Heitzer, E; Quehenberger, F; Daga, S; Hofer, S; Halbwedl, I; Graf, R; Krisper, N; Hoefler, G; Zebisch, A; Sill, H; Wölfler, A
Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia.
Am J Hematol. 2018; 93(1):23-30
Doi: 10.1002/ajh.24922
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Huemer, F; Weiss, L; Faber, V; Neureiter, D; Egle, A; Geissler, K; Voskova, D; Zebisch, A; Burgstaller, S; Pichler, A; Stauder, R; Sperr, W; Lang, A; Pfeilstöcker, M; Machherndl-Spandl, S; Stampfl, M; Greil, R; Pleyer, L
Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.
Wien Klin Wochenschr. 2018; 130(3-4):115-125
Doi: 10.1007/s00508-018-1315-2
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Short report/Letter
** Kashofer, K; Gornicec, M; Lind, K; Caraffini, V; Schauer, S; Beham-Schmid, C; Wölfler, A; Hoefler, G; Sill, H; Zebisch, A
Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing.
Leuk Lymphoma. 2018; 59(2):501-504
Doi: 10.1080/10428194.2017.1339879
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Caraffini, V; Geiger, O; Rosenberger, A; Hatzl, S; Perfler, B; Berg, JL; Lim, C; Strobl, H; Kashofer, K; Hoefler, G; Geissler, K; Kolch, W; Blyth, K; Athineos, D; Wolfler, A; Sill, H; Zebisch, A
Loss of RKIP expression is a frequent event in chronic myelomonocytic leukemia and functionally involved in the pathogenesis of this malignancy
ONCOL RES TREAT. 2018; 41: 27-27.
[Oral Communication]
Web of Science
** Daga, S; Rosenberger, A; Krisper, N; Prietl, B; Reinisch, A; Zebisch, A; Sill, H; Wolfler, A
GPR56 and CLL-1 (CLEC12A) as putative leukemic stem cell markers in CD34-positive acute myeloid leukemia
ONCOL RES TREAT. 2018; 41: 73-73.
[Poster]
Web of Science
** Geissler, K; Barna, A; Jager, E; Gurbisz, M; Alendar, T; Ljubuncic, E; Jilch, R; Nosslinger, T; Pfeilstocker, M; Tuchler, H; Reisner, R; Sliwa, T; Keil, F; Geissler, C; Burgstaller, S; Thaler, J; Machherndl-Spandl, S; Zach, O; Weltermann, A; Bettelheim, P; Stauder, R; Borjan, B; Zebisch, A; Sill, H; Schwarzinger, I; Hormann, G; Jager, U; Sperr, WR; Knobl, P; Schneeweiss, B; Berger, J; Ohler, L; Ulsperger, E; Kusec, R; Germing, U; Valent, P
The role of RAS pathway hyperactivation in the progression and transformation of chronic myelomonocytic leukemia
ONCOL RES TREAT. 2018; 41: 238-238.
[Oral Communication]
Web of Science
** Hatzl, S; Ebner, S; Perfler, B; Quehenberger, F; Troppmair, J; Reinisch, A; Wolfler, A; Sill, H; Zebisch, A
Deregulation of the micro-RNA-23a/TOP2B axis causes resistance to cytarabine in acute myeloid leukemia
ONCOL RES TREAT. 2018; 41: 243-243.
[Oral Communication]
Web of Science
** Muralikrishnan, AS; Rosenberger, A; Schwarzenberger, E; Strobl, H; Zebisch, A; Sill, H; Wolfler, A
A role of C/EBP alpha in early dendritic cell development
ONCOL RES TREAT. 2018; 41: 102-102.
[Poster]
Web of Science
** Pabst, G; Prochazka, K; Pregartner, G; Rücker, FG; Heitzer, E; Woelfler ,A; Zebisch, A; Berghold, A; Döhner, K; Sill H.
Impact of TP53 mutated subclones in acute myeloid leukemia
Blood. 2018; 132(Suppl ):-Annual Meeting of the American Society of Hematology; December 1-4, 2018; San Diego.
Doi: 10.1182/blood-2018-99-110667
[Poster]
Web of Science
FullText
FullText_MUG
2017
Full paper/article (Journal)
** Lal, R; Lind, K; Heitzer, E; Ulz, P; Aubell, K; Kashofer, K; Middeke, JM; Thiede, C; Schulz, E; Rosenberger, A; Hofer, S; Feilhauer, B; Rinner, B; Svendova, V; Schimek, MG; Rücker, FG; Hoefler, G; Döhner, K; Zebisch, A; Wölfler, A; Sill, H
Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia.
Blood. 2017; 129(18): 2587-2591.
Doi: 10.1182/blood-2016-11-751008
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Magina, KN; Pregartner, G; Zebisch, A; Wölfler, A; Neumeister, P; Greinix, HT; Berghold, A; Sill, H
Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
Blood. 2017; 130(7): 946-948.
Doi: 10.1182/blood-2017-04-777722
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Pleyer, L; Döhner, H; Dombret, H; Seymour, JF; Schuh, AC; Beach, CL; Swern, AS; Burgstaller, S; Stauder, R; Girschikofsky, M; Sill, H; Schlick, K; Thaler, J; Halter, B; Machherndl Spandl, S; Zebisch, A; Pichler, A; Pfeilstöcker, M; Autzinger, EM; Lang, A; Geissler, K; Voskova, D; Sperr, WR; Hojas, S; Rogulj, IM; Andel, J; Greil, R
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Int J Mol Sci. 2017; 18(2):
Doi: 10.3390/ijms18020415
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Stauber, MN; Aberer, F; Oulhaj, A; Mader, JK; Zebisch, A; Pieber, TR; Neumeister, P; Greinix, HT; Sill, H; Sourij, H; Wölfler, A
Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease.
Biol Blood Marrow Transplant. 2017; 23(7):1186-1192
Doi: 10.1016/j.bbmt.2017.03.010
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Short report/Letter
** Aberer, F; Kremser, S; Mader, JK; Zinke-Cerwenka, W; Greinix, H; Tripolt, NJ; Pieber, TR; Zebisch, A; Sill, H; Oulhaj, A; Sourij, H; Wölfler, A
Hyperglycaemia within the first month after allogeneic haematopoietic stem-cell transplantation is an independent risk factor for overall survival in patients with acute myeloid leukaemia.
Diabetes Metab. 2017; 43(6):560-562
Doi: 10.1016/j.diabet.2017.02.001
Web of Science
PubMed
FullText
FullText_MUG
** Gornicec, M; Wölfler, A; Stanzel, S; Sill, H; Zebisch, A
Evidence for a role of decitabine in the treatment of myeloid sarcoma.
Ann Hematol. 2017; 96(3):505-506
Doi: 10.1007/s00277-016-2870-0
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Aberer, F; Holzgruber, J; Tripolt, NJ; Zebisch, A; Greinix, H; Sill, H; Mader, JK; Pieber, TR; Wölfler, A; Sourij, H
Efficacy and safety of an insulin decision support system in the treatment of steroid hyperglycaemia in patients with graft-versus- host-disease: a randomised pilot trial.
Diabetologia. 2017; 60(S1):S323-S324.-53rd Annual Meeting of the European Association for the Study of Diabetes (EASD); SEP 11-15, 2017; Lisbon, PORTUGAL.
[Poster]
Web of Science
** Caraffini, V; Geiger, O; Rosenberger, A; Hatzl, S; Perfler, B; Berg, JL; Lim, C; Strobl, H; Kashofer, K; Hoefler, G; Geissler, K; Kolch, W; Blyth, K; Athineos, D; Woelfler, A; Sill, H; Zebisch, A
LOSS OF RAF KINASE INHIBITOR PROTEIN IS INVOLVED IN MYELOMONOCYTIC LINEAGE COMMITMENT AND AGGRAVATES THE DEVELOPMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN A MURINE IN-VIVO MODEL
HAEMATOLOGICA. 2017; 102: 148-149.-22nd Congress of the European-Hematology-Association; JUN 22-25, 2017; Madrid, SPAIN.
[Oral Communication]
Web of Science
** Caraffini, V; Schauer, S; Kashofer, K; Wolfler, A; Hoefler, G; Sill, H; Zebisch, A
RAF KINASE INHIBITOR PROTEIN IS INVOLVED IN THE DEVELOPMENT OF MYELOID SARCOMA
HAEMATOLOGICA. 2017; 102: 361-362.-22nd Congress of the European-Hematology-Association; JUN 22-25, 2017; Madrid, SPAIN.
[Poster]
Web of Science
** Gaksch, L; Kashofer, K; Heitzer, E; Daga, S; Hofer, S; Krisper, N; Hofler, G; Zebisch, A; Sill, H; Wolfler, A
Persistence of non-DNMT3A mutations predicts relapse in cytogenetically normal AML
ONCOL RES TREAT. 2017; 40: 140-141.
[Oral Communication]
Web of Science
** Geissler, K; Barna, A; Jäger, E; Alendar, T; Ljubuncic, E; Jilch, R; Nösslinger, T; Pfeilstöcker, M; Tüchler, H; Reisner, R; Sliwa, T; Keil, F; Burgstaller, S; Thaler, J; Machherndl-Spandl, S; Zach, O; Weltermann, A; Bettelheim, P; Stauder, R; Schwarzinger, I; Hörmann, G; Jäger, U; Sperr, RW; Knöbl, P; Schneeweiss, B; Berger, J; Kusec, R; Öhler, L; Zebisch, A; Sill, H; Germing, U; Valent, P
High spontaneous in-vitro myeloid colony growth is an adverse risk factor in chronic myelomonocytic leukemia
Oncol Res Treat. 2017; 40(S3):131-131.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; SEP 29 - OCT 3, 2017; Stuttgart, GERMANY. (ISBN: 978-3-318-06110-9 )
[Oral Communication]
Web of Science
** Stauber, M; Aberer, F; Oulhaj, A; Mader, JK; Zebisch, A; Pieber, TR; Neumeister, P; Greinix, HT; Sill, H; Sourij, H; Wolfler, A
Early hyperglycaemia after initiation of glucocorticoid therapy predicts adverse outcome in patients with acute graft-versus-host disease
BONE MARROW TRANSPL. 2017; 52: S285-S285.
Web of Science
2016
Full paper/article (Journal)
** Bainschab, A; Quehenberger, F; Greinix, HT; Krause, R; Wölfler, A; Sill, H; Zebisch, A
Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis.
Leuk Res. 2016; 42(3):47-51
Doi: 10.1016/j.leukres.2016.01.014
Web of Science
PubMed
FullText
FullText_MUG
** Dernayka, L; Rauch, N; Jarboui, MA; Zebisch, A; Texier, Y; Horn, N; Romano, D; Gloeckner, CJ; Kriegsheim, Av; Ueffing, M; Kolch, W; Boldt, K
Autophosphorylation on S614 inhibits the activity and the transforming potential of BRAF.
Cell Signal. 2016; 28(9):1432-1439
Doi: 10.1016/j.cellsig.2016.06.016
Web of Science
PubMed
FullText
FullText_MUG
** Hatzl, S; Geiger, O; Kuepper, MK; Caraffini, V; Seime, T; Furlan, T; Nussbaumer, E; Wieser, R; Pichler, M; Scheideler, M; Nowek, K; Jongen-Lavrencic, M; Quehenberger, F; Wölfler, A; Troppmair, J; Sill, H; Zebisch, A
Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP.
Cancer Res. 2016; 76(12):3644-3654
Doi: 10.1158/0008-5472.CAN-15-3049
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Sill, H; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Zebisch, A; Pichler, A; Pfeilstöcker, M; Autzinger, EM; Lang, A; Geissler, K; Voskova, D; Geissler, D; Sperr, WR; Hojas, S; Rogulj, IM; Andel, J; Greil, R
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
J Hematol Oncol. 2016; 9(6):39-39
Doi: 10.1186/s13045-016-0263-4
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Zebisch, A; Lal, R; Müller, M; Lind, K; Kashofer, K; Girschikofsky, M; Fuchs, D; Wölfler, A; Geigl, JB; Sill, H
Acute myeloid leukemia with TP53 germ line mutations.
Blood. 2016; 128(18): 2270-2272.
Doi: 10.1182/blood-2016-08-732610
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Short report/Letter
** Sill, H; Kqiku-Kryeziu, X; Avian, A; Kovacs, G; Gaal, S; Zebisch, A; Olschewski, H
Pulmonary arterial pressure in patients with myelodysplastic syndromes.
Leuk Lymphoma. 2016; 57(11):2723-2726
Doi: 10.3109/10428194.2016.1160086
Web of Science
PubMed
FullText
FullText_MUG
Review
** Zebisch, A; Hatzl, S; Pichler, M; Wölfler, A; Sill, H
Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs.
Int J Mol Sci. 2016; 17(12):
Doi: 10.3390/ijms17122080
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Gaksch, L; Kashofer, K; Heitzer, E; Daga, S; Hofer, S; Krisper, N; Höfler, G; Zebisch, A; Sill, H; Wölfler A
Persitence of non-DNMT3A mutations predicts relapse in cytogenetically normal AML.
Oncol Res Treat 2016. 2016; 39(suppl3):140--Jahrestagung DGHO; OCT 14-18,2016; Leipzig. (ISBN: 2296-5270 )
[Oral Communication]
Web of Science
** Olipitz, W; Lind, K; Monsberger, N; Katschnig, A; Mangerich, A; Rankl, J; Hofer, S; Mueller, M; Schulz, E; Quehenberger, F; Schlembach, D; Robier, C; Woelfler, A; Zebisch, A; Sill, H
IMPAIRED BASE EXCISION REPAIR GLYCOSYLASE/AP ENDONUCLEASE ACTIVITY CONTRIBUTES TO CYTARABINE RESISTANCE IN ACUTE MYELOID LEUKEMIA
HAEMATOLOGICA. 2016; 101: 211-212.
[Poster]
Web of Science
** Zebisch, A; Lal, R; Muller, M; Lind, K; Sill, H
TP53 germline mutations occur in acute myeloid leukemia and are associated with therapy-related cases following ionizing radiation
WIEN KLIN WOCHENSCHR. 2016; 128: S385-S386.
[Poster]
Web of Science
2015
Full paper/article (Journal)
** Milewska, M; Romano, D; Herrero, A; Guerriero, ML; Birtwistle, M; Quehenberger, F; Hatzl, S; Kholodenko, BN; Segatto, O; Kolch, W; Zebisch, A
Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation.
PLoS One. 2015; 10(6):e0129859-e0129859
Doi: 10.1371/journal.pone.0129859
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Short report/Letter
** Geiger, O; Hatzl, S; Kashofer, K; Hoefler, G; Wölfler, A; Sill, H; Zebisch, A
Deletion of SPRY4 is a frequent event in secondary acute myeloid leukemia.
Ann Hematol. 2015; 94(11):1923-1924
Doi: 10.1007/s00277-015-2445-5
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Zebisch, A; Schulz, E; Grosso, M; Lombardo, B; Acierno, G; Sill, H; Iolascon, A
Identification of a novel variant of epsilon-gamma-delta-beta thalassemia highlights limitations of next generation sequencing.
Am J Hematol. 2015; 90(3): E52-E54.
Doi: 10.1002/ajh.23913
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Aberer, F; Mader, JK; Kremser, S; Zinke-Cerwenka, W; Greinix, H; Pieber, TR; Zebisch, A; Sill, H; Oulhaj, A; Wölfler, A; Sourij, H
Glykämie nach allogener Stammzelltransplantation bei Patienten mit akuter myeloischer Leukämie (AML) ist ein unabhängiger Prädiktor für das Überleben.
Wiener Klinische Wochenschrift. 2015; 127(Suppl 4 ):S135-S135.-43. Jahrestagung der Österreichischen Diabetes Gesellschaft (ÖDG); NOV 19-21, 2015; Salzburg, AUSTRIA.
[Poster]
Web of Science
** Bainschab, A; Quehenberger, F; Greinix, HT; Krause, R; Wolfler, A; Sill, H; Zebisch, A
Efficacy of antibiotic prophylaxis in AML patients treated with low-intensity therapeutic regimens
ONCOL RES TREAT. 2015; 38: 73-74.
[Poster]
Web of Science
** Hatzl, S; Geiger, O; Kuepper, MK; Seime, T; Nussbaumer, E; Wieser, R; Pichler, M; Scheideler, M; Nowek, K; Jongen-Lavrencic, M; Wolfler, A; Troppmair, J; Sill, H; Zebisch, A
Loss of the tumor- and metastasis suppressor RAF kinase inhibitor protein is caused by the overexpression of miRNA-23a
ONCOL RES TREAT. 2015; 38: 99-99.
[Oral Communication]
Web of Science
** Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Sill, H; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Zebisch, A; Pichler, A; Pfeilstöcker, M; Autzinger, EM; Lang, A; Geissler, K; Voskova, D; Geissler, D; Sperr, WR; Hojas, S; Mandac-Rogulj, I; Andel, J; Greil, R
Is it time to redefine response or treatment failure in elderly patients with WHO-AML unfit for intensive chemotherapy?
Blood 2015. 2015; 126(23):-Annual meeting of the American Society of Hematology; DEC 5-8, 2015; Orlando, USA.
[Poster]
Web of Science
** Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Sill, H; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Zebisch, A; Pichler, A; Pfeilstöcker, M; Autzinger, EM; Lang, A; Geissler, K; Voskova, D; Geissler, D; Sperr, WR; Hojas, S; Mandac-Rogulj, I; Andel, J; Greil, R
Azacitidine in acute myeloid leukemia with >30% bone marrow blasts and <15 G/L white blood cell count: Results from the Austrian Azacitidine Registry of the AGMT Study Group versus randomized controlled phase III clinical trial data.
Blood 2015. 2015; 126(23):-Annual Meeting of the American Society of Hematology; DEC 5-8, 2015; Orlando, USA.
[Poster]
Web of Science
** Rosenberger, A; Geiger, O; Zebisch, A; Sill, H; Wolfler, A
C/EBP alpha-induced proinflammatory cytokines regulate early dendritic cell development
ONCOL RES TREAT. 2015; 38: 249-250.
[Poster]
Web of Science
** Stauber, M; Aberer, F; Zebisch, A; Neumeister, P; Greinix, HT; Sill, H; Sourij, H; Wolfler, A
Steroid-induced hyperglycemia adversely impacts outcome in graft-versus-host disease
ONCOL RES TREAT. 2015; 38: 129-129.
[Poster]
Web of Science
2014
Full paper/article (Journal)
** Schulz, E; Klampfl, P; Holzapfel, S; Janecke, AR; Ulz, P; Renner, W; Kashofer, K; Nojima, S; Leitner, A; Zebisch, A; Wölfler, A; Hofer, S; Gerger, A; Lax, S; Beham-Schmid, C; Steinke, V; Heitzer, E; Geigl, JB; Windpassinger, C; Hoefler, G; Speicher, MR; Boland, CR; Kumanogoh, A; Sill, H
Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X.
Nat Commun. 2014; 5(10):5191-5191
Doi: 10.1038/ncomms6191
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Olipitz, W; Lind, K; Monsberger, N; Katschnig, A; Mangerich, A; Hofer, S; Schulz, E; Quehenberger, F; Schlembach, D; Robier, C; Woelfler, A; Zebisch, A; Sill, H
Base Excision Repair Glycosylase Activity Is Impaired in a Subgroup of Acute Myeloid Leukemia Resulting in Increased Levels of Oxidative Base Lesions
BLOOD. 2014; 124(21):-56th Annual Meeting of the American-Society-of-Hematology; DEC 06-09, 2014; San Francisco, CA.
[Poster]
Web of Science
** Olipitz, W; Lind, K; Monsberger, N; Katschnig, A; Mangerich, A; Hofer, S; Schulz, E; Quehenberger, F; Schlembach, D; Robier, C; Wölfler, A; Zebisch, A; Sill, H
Base excision repair glycosylase activity is impaired in a subgroup of acute myeloid leukemia resulting in increased levels of oxidative base lesions
Oncol Res Treat. 2014; 37(S5):49-49.-Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology; OCT 10-14; Hamburg, GERMANY. (ISBN: 978-3-318-02811-9 )
[Poster]
Web of Science
** Schulz, E; Klampfl, P; Holzapfel, S; Janecke, AR; Ulz, P; Renner, W; Kashofer, K; Najima, S; Leitner, A; Zebisch, A; Wölfler, A; Hofer, S; Gerger, A; Lax, S; Beham-Schmid, C; Steinke, V; Geigl, JB; Höfler, G; Speicher, MR; Boland, CR; Kumanogoh, A; Sill, H
Germline variants in the semaphorin SEMA4A confer susceptibility to familial colorectal cancer type X
Oncol Res Treat. 2014; 37(S5):105-105.-Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology; OCT 10-14, 2014; Hamburg, GERMANY. (ISBN: 978-3-318-02811-9 )
[Oral Communication]
Web of Science
** Wölfler, A; Rosenberger, A; Wolf, O; Zebisch, A; Touw, IP; Sill, H
A role of C/EBP-Alpha in Development of Plasmacytoid Dendritic Cells in the Thymus
Haematologica. 2014; 99(S1):174-174.-19th Congress of European Hematology Association; JUN 12-15, 2014; Milan, ITALY.
[Poster]
Web of Science
** Zebisch, A; Wolf, O; Rosenberger, A; Petricevic, P; Hatzl, S; Troppmair, J; Kolch, W; Blyth, K; Haller, M; Sill, H; Woelfler, A
RAF kinase inhibitor protein is involved in the regulation of myelomonocytic differentiation.
Oncol Res Treat. 2014; 37(S5):49-49. 2014; 37(S5):24-24.-Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology; OCT 10-14; Hamburg. (ISBN: 978-3-318-0281 )
[Oral Communication]
Web of Science
2013
Full paper/article (Journal)
** Gary, T; Belaj, K; Bruckenberger, R; Hackl, G; Hafner, F; Froehlich, H; Zebisch, A; Pilger, E; Brodmann, M
Primary antiphospholipid antibody syndrome-one further aspect of thrombophilia in overweight and obese patients with venous thromboembolism.
Obesity (Silver Spring). 2013; 21(9):E463-E466
Doi: 10.1002/oby.20188
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Troch, M; Kiesewetter, B; Willenbacher, W; Willenbacher, E; Zebisch, A; Linkesch, W; Fridrik, M; Müllauer, L; Greil, R; Raderer, M
Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie.
Haematologica. 2013; 98(2):264-268
Doi: 10.3324/haematol.2012.072587
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Short report/Letter
** Zebisch, A; Hoefler, G; Quehenberger, F; Wölfler, A; Sill, H
Mutant DNMT3A in acute myeloid leukemia: guilty of inducing genetic instability?
Leukemia. 2013; 27(8): 1777-1778.
Doi: 10.1038/leu.2013.48
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Hoenigl, M; Duettmann, W; Huber-Krassnitzer, B; Theiler, G; Raggam, RB; Prueller, F; Zebisch, A; Neumeister, P; Wagner, J; Seeber, K; Wolfler, A; Krause, R;
Impact of structured on-site patient education on low posaconazole plasma concentrations.
MYCOSES. 2013; 56: 47-47.-6th Trends in Medical Mycology; OCT 11-14, 2013; Kopenhagen, DENMARK.
[Oral Communication]
Web of Science
2012
Full paper/article (Journal)
** Schulz, E; Valentin, A; Ulz, P; Beham-Schmid, C; Lind, K; Rupp, V; Lackner, H; Wölfler, A; Zebisch, A; Olipitz, W; Geigl, J; Berghold, A; Speicher, MR; Sill, H
Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
J Med Genet. 2012; 49(7):422-428
Doi: 10.1136/jmedgenet-2011-100674
Web of Science
PubMed
FullText
FullText_MUG
** Zebisch, A; Wölfler, A; Fried, I; Wolf, O; Lind, K; Bodner, C; Haller, M; Drasche, A; Pirkebner, D; Matallanas, D; Rath, O; Blyth, K; Delwel, R; Taskesen, E; Quehenberger, F; Kolch, W; Troppmair, J; Sill, H
Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia.
Leukemia. 2012; 26(8):1842-1849
Doi: 10.1038/leu.2012.61
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Short report/Letter
** Fried, I; Wölfler, A; Quehenberger, F; Hoefler, G; Sill, H; Zebisch, A
Mutations inDNMT3A and loss of RKIP are independent events in acute monocytic leukemia.
Haematologica. 2012; 97(12):1936-1937
Doi: 10.3324/haematol.2012.068429
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Schulz, E; Valentin, A; Ulz, P; Beham-Schmid, C; Lind, K; Rupp, V; Lackner, H; Wolfler, A; Zebisch, A; Olipitz, W; Geigl, JB; Berghold, A; Speicher, MR; Sill, H
Germ-line mutations in cancer predisposing genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy-related myeloid neoplasms.
ONKOLOGIE. Onkologie. 2012; 35: 117-117.-Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology; OCT 19-23, 2012; Stuttgart, GERMANY.
[Poster]
Web of Science
** Troch, M; Kiesewetter, B; Willenbacher, W; Willenbacher, E; Zebisch, A; Linkesch, W; Fridrik, MA; Müllauer, L; Greil, R; Raderer, M
Rituximab plus subcutaneous Cladribine in patients with extranodal marginal zone B-cell Lymphoma of the Mucosa associated tissue (MALT-Lymphoma): A Phase II study by the AGMT
Annals of Oncology. 2012; 23(9):352-352.-37th ESMO Congress; SEP 28-OCT 2, 2012; VIENNA, AUSTRIA. (ISBN: 1569-8041 )
[Poster]
Web of Science
2011
Full paper/article (Journal)
** Matallanas, D; Birtwistle, M; Romano, D; Zebisch, A; Rauch, J; von Kriegsheim, A; Kolch, W
Raf family kinases: old dogs have learned new tricks.
Genes Cancer. 2011; 2(3):232-260
Doi: 10.1177/1947601911407323
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
Review
** Sill, H; Olipitz, W; Zebisch, A; Schulz, E; Wölfler, A
Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.
Br J Pharmacol. 2011; 162(4): 792-805.
Doi: 10.1111/j.1476-5381.2010.01100.x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Proceedings)
** Zebisch, A; Wölfler, A; Hiden K; Bodner, C; Quehenberger, F; Drasche, A; Pirkebner, D; Haller, M; Matallanas, D; Fried, I; Rath, O; Blyth, K; Taskesen, E; Kolch, W; Troppmair, J; Sill, H
RAF kinase inhibitor protein ist ein neuer Tumor-Suppressor bei der akuten myeloischen Leukämie
Onkologie. 2011; 34(S6):209-209.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie; SEP 30-OCT 4, 2011; Basel, Switzerland. (ISBN: 978-3-8055-9922-1 )
[Oral Communication]
Web of Science
FullText
2010
Full paper/article (Journal)
** Shin, SY; Rath, O; Zebisch, A; Choo, SM; Kolch, W; Cho, KH
Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition.
Cancer Res. 2010; 70(17): 6715-6724.
Doi: 10.1158/0008-5472.CAN-10-1377
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Short report/Letter
** Zach, J; Zollner-Schwetz, I; Zebisch, A; Rohn, A; Sill, H; Krause, R
Gram stain/aolc screening for detection of catheter related bloodstream infection.
J Infect. 2010; 60(3): 254-255.
Doi: 10.1016/j.jinf.2010.01.001
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Haller, M; Zebisch, A; Hiden, K; Hoefler, G; Sill, H; Troppmair, J
Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations
FEBS J. 2010; 277: 127-127.
[Poster]
Web of Science
** Zebisch, A; Woelfler, A; Hiden, K; Bodner, C; Quehenberger, F; Drasche, A; Pirkebner, D; Haller, M; Rath, O; Blyth, K; Taskesen, E; Kolch, W; Troppmair, J; Sill, H
Loss of RAF Kinase Inhibitor Protein Is a Frequent Event In Acute Myeloid Leukemia with a Monocytic Phenotype and Cooperates with Mutant RAS In Malignant Transformation
BLOOD. 2010; 116(21): 1702-1702.
[Poster]
Web of Science
** Zebisch, A; Woelfler, A; Hiden, K; Bodner, C; Quehenberger, F; Drasche, A; Pirkebner, D; Rath, O; Blyth, K; Delwel, R; Taskesen, E; Kolch, W; Troppmair, J; Sill, H
LOSS OF RKIP IN ACUTE MYELOID LEUKEMIA WITH A MONOCYTIC PHENOTYPE
HAEMATOL-HEMATOL J. 2010; 95: 0026 -Annual Meting of the European Haematology Association; June 2010; Barcelona.
[Poster]
Web of Science
2009
Full paper/article (Journal)
** Zebisch, A; Haller, M; Hiden, K; Goebel, T; Hoefler, G; Troppmair, J; Sill, H
Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations.
Leukemia. 2009; 23(6): 1049-1053.
Doi: 10.1038/leu.2009.68
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2008
Full paper/article (Journal)
** Novak, M; Hiden, M; Rehak, T; Rosenkranz, A; Zebisch, A; Sill, H; Klaschka, S; Muntean, W
Enhanced thrombin generation in plasma of severe thrombocytopenic patients due to rFVIIa.
HAMOSTASEOLOGIE. 2008; 28 Suppl 1(12): S77-S80.
Doi: 10.1055/s-0037-1621422
Web of Science
PubMed
FullText
FullText_MUG
** Zebisch, A; Sill, H
Severe hemolysis as presenting sign of acute erythroleukemia.
J Clin Oncol. 2008; 26(2): 330-331.
Doi: 10.1200/JCO.2007.14.1481
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Short report/Letter
** Zebisch, A; Sill, H
Are mouthwashes a reliable source of constitutional DNA in patients with leukemia?
Leuk Res. 2008; 32(7): 1164-1165.
Doi: 10.1016/j.leukres.2007.11.003
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Novak, M; Rosenkranz, A; Muntean, W; Zebisch, A; Sill, H; Hiden, M
Recombinant factor VIIa enhances thrombin generation in plasma of severe thrombocytopenic patients.
HAEMOPHILIA. HAEMOPHILIA2008; 14: 9-9.-World Hemophilia Congress ; JUN 2-5, 2008; Istanbul, TÜRKEI.
[Oral Communication]
Web of Science
** Reitter, S; Zinke-Cerwenka, W; Zebisch, A; Sormann, S; Sill, H; Linkesch, W
Haematopoetic stem cell transplantation in CLL: promising results using allogeneic reduced intensity conditioning compared with an autologous setting
BONE MARROW TRANSPLANT. 2008; 41: S309-S310.-34th Meeting oif the EBMT; MARCH 30- APR 2, 2008; Florence, ITALY.
[Poster]
Web of Science
** Zach, J; Zollner-Schwetz, I; Zebisch, A; Rohn, A; Krause, R
Mikrobiologisches Screening zur Detektion von Katheter-assoziierten Bakteriämien/Fungämien bei Patienten im Rahmen einer hämatopoetischen Stammzelltransplantation.
. 2008; 120(15): A48
[Poster]
Web of Science
** Zinke-Cerwenka, W; Posch, U; Zebisch, A; Linkesch, W; Sill, H
Results of umbilical cord blood transplantations in adults with high-risk haematologic malignancies
BONE MARROW TRANSPLANT. BONE MARROW TRANSPLANTATION.2008; 41: S158-S158.-34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group; MAR 30-APR 02, 2008; Florence, ITALY.
[Poster]
Web of Science
** Zinke-Cerwenka, W; Stojakovic, T; Zebisch, A; Sill, H; Linkesch, W
Promising results in multiple myeloma patients treated with induction chemotherapy consisting of bortezomib, doxorubicin and dexamethasone followed by autologous stem cell transplantation
BONE MARROW TRANSPLANT. 2008; 41: S185-S185.-34th Meeting of the EBMT; March 30- APR 2, 2008;
[Poster]
Web of Science
2007
Review
** Zebisch, A; Czernilofsky, AP; Keri, G; Smigelskaite, J; Sill, H; Troppmair, J
Signaling through RAS-RAF-MEK-ERK: from basics to bedside.
Curr Med Chem. 2007; 14(5): 601-623.
Doi: 10.2174/092986707780059670
Web of Science
PubMed
FullText
FullText_MUG
2006
Full paper/article (Journal)
** Zebisch, A; Staber, PB; Delavar, A; Bodner, C; Hiden, K; Fischereder, K; Janakiraman, M; Linkesch, W; Auner, HW; Emberger, W; Windpassinger, C; Schimek, MG; Hoefler, G; Troppmair, J; Sill, H
Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.
Cancer Res. 2006; 66(7):3401-3408
Doi: 10.1158/0008-5472.CAN-05-0115
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Review
** Zebisch, A; Troppmair, J
Back to the roots: the remarkable RAF oncogene story.
CELL MOL LIFE SCI. 2006; 63: 1314-1330.
Doi: 10.1007/s00018-006-6005-y
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Langner, S; Staber, PB; Zebisch, A; Zinke-Cerwenka, W; Sill, H; Linkesch, W; Greinix, H; Kalhs, P; Rabitsch, W; Neumeister, P
Adding palifermin in allogeneic and autologous stem cell transplantation resulted in reduced oral mucositis and enhanced intestinal mucosal recovery measured by citrulline serum levels.
BLOOD. 2006; 108(11): 404B-404B.
Doi: 10.1182/blood.V108.11.5251.5251
[Poster]
Web of Science
FullText
FullText_MUG
2005
Full paper/article (Journal)
** Auner, HW; Zebisch, A; Ofner, P; Sill, H; Linkesch, W; Krause, R
Evaluation of potential risk factors for early infectious complications after autologous peripheral blood stem cell transplantation in patients with lymphoproliferative diseases.
ANN HEMATOL. 2005; 84: 532-537.
Doi: 10.1007/s00277-005-1025-5
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
** Zebisch, A; Linkesch, W; Sill, H
Bedside RNA stabilizing kit systems for gene expression analysis of acute leukemias: influence of non-neoplastic white blood cells.
Leukemia. 2005; 19(4):685-685
Doi: 10.1038/sj.leu.2403713
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Short report/Letter
** Zebisch, A; Linkesch, W; Sill, H
Bedside RNA stabilizing kit systems for gene expression analysis of acute leukemias: influence of non-neoplastic white blood cells.
LEUKEMIA. 2005; 19: 136-137.
Doi: 10.1038/sj.leu.2403581
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2004
Full paper/article (Journal)
** Auner, HW; Zebisch, A; Schimek, MG; Bodner, C; Hiden, K; Linkesch, W; Haas, OA; Beham-Schmid, C; Sill, H
High expression of the sister-chromatid separation regulator and proto-oncogene hSecurin occurs in a subset of myeloid leukaemias but is not implicated in the pathogenesis of aneuploidy.
Leukemia. 2004; 18(2):303-308
Doi: 10.1038/sj.leu.2403235
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Zebisch, A; Staber, PB; Fischereder, K; Bodner, C; Hiden, K; Linkesch, W; Auner, HW; Emberger, W; Windpassinger, C; Schimek, MG; Hoefler, G; Troppmair, J; Sill, H
Two novel activating germline mutations of the C-RAF proto-oncogene predisposing to solid tbmors and therapy-related acute myeloid leukemia.
BLOOD 2004 104: 920A-920A.
Doi: 10.1182/blood.V104.11.3370.3370
Web of Science
FullText
FullText_MUG
2003
Full paper/article (Journal)
** Zebisch, A; Cerroni, L; Beham-Schmid, C; Sill, H
Therapy-related leukemia cutis: case study of an aggressive disorder.
ANN HEMATOL 2003 82: 705-707.
Doi: 10.1007/s00277-003-0717-y
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar